Pediatric Extracorporeal Membrane Oxygenation Anticoagulation and Monitoring: Where We Were and Where Are We Now?

Area of Science:

• Pediatric critical care medicine
• Cardiovascular support technologies
• Hematology and thrombosis

Background:

• Extracorporeal membrane oxygenation (ECMO) is a vital life support technology for neonates and children with severe cardiorespiratory failure.
• Technological advancements in ECMO have paralleled increasing interest in optimizing anticoagulation strategies for pediatric patients.
• Effective anticoagulation and vigilant laboratory monitoring are crucial for safe and successful ECMO therapy in pediatric populations.

Purpose of the Study:

• To review current evidence on anticoagulation agents used in pediatric ECMO.
• To summarize laboratory monitoring strategies for anticoagulation in pediatric ECMO.
• To provide clinical guidance for managing anticoagulation in neonates and children undergoing ECMO.

Main Methods:

• Comprehensive literature search of peer-reviewed articles and clinical guidelines.
• Synthesis of evidence regarding various anticoagulation agents (e.g., heparin, direct thrombin inhibitors).
• Analysis of laboratory monitoring parameters (e.g., aPTT, anti-Xa levels) and their interpretation in pediatric ECMO.

Main Results:

• Evidence supports the use of specific anticoagulation agents, with tailored dosing based on patient factors and monitoring.
• Various laboratory assays are employed for monitoring, each with advantages and limitations in the pediatric ECMO context.
• Optimal anticoagulation targets may vary, necessitating individualized approaches and frequent reassessment.

Conclusions:

• Anticoagulation management in pediatric ECMO requires a multidisciplinary approach, integrating pharmacologic knowledge with laboratory data.
• Standardized protocols and continuous evaluation of monitoring strategies are essential for improving patient outcomes.
• Further research is needed to establish definitive best practices for anticoagulation in this vulnerable patient group.